-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoCAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration
Shinshu University Hospital's expertise in CAR T-cell therapy R&D and clinical application will be combined with Teijin Regenet's manufacturing and quality-management expertise cultivated through its CDMO...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agomRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoEncoded raises $275M series F for Dravet syndrome gene therapy
Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoSTAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical trial of its gene therapy for Huntington’s disease.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoSynthetic biology
Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03289-9Recent patents relating to systems, methods and compositions for use in synthetic biology.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoBrainChild: Bringing CAR Ts directly to the brain
BIOCENTURY | EMERGING COMPANY PROFILEBRAINCHILD: BRINGING CAR TS DIRECTLY TO THE BRAINRepeat dosing into the CSF is designed to sidestep the toxicities that have limited CNS-directed...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoGene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat Model
Intravenous gene therapy extended lifespan, reduced neurological symptoms, and improved disease markers in a Sandhoff disease cat model, supporting further investigation of systemic AAV gene therapy...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoBMS eyes role for new CAR-T in post-BCMA multiple myeloma
BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoBMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences,...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months ago
A translational framework for extrahepatic oligonucleotide delivery
Nature Reviews Drug Discovery, Published online: 09 September 2026; doi:10.1038/d41573-026-00125-2To unlock the ‘plug-and-play’ potential of extrahepatic delivery of oligonucleotide-based drugs, the field must bridge the gap...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
